Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
According to the terms of the agreement, the two parties will jointly develop new adjuvant vaccines. Recbio will provide its new adjuvant independently developed based on the new adjuvant technology platform, and Rongsheng Biotech will provide its independently designed viral antigen. This project will empower existing Rongsheng Biotech vaccines under development with new adjuvants to improve immunogenicity and optimize the vaccination program.
Dr.
Zhu Shaorong, founder and chairman of Rongsheng Biotech, said: "Rongsheng Biotech has built a key core technology platform for 'virus + bacteria 'vaccines based on independent innovation and research and development. It has large-scale production capabilities and has achieved technological innovation and upgrade breakthroughs in scientific research on a number of vaccine products under development. This strategic cooperation aims at cutting-edge vaccine innovation and market demand, making full use of the scientific research advantages and innovative achievements of both parties, and continuing to in-depth cooperation to jointly promote the development and commercialization of new adjuvant vaccines. We are full of confidence in working with Recbio to achieve strategic cooperation results and benefit human life and health and public health security with better clinical performance."
About Recbio
Founded in 2012,
Leveraging the close integration of our three platforms, we are consistently creating promising vaccine candidates. Fueled by these innovative platforms, the Company has forged a high-value portfolio of innovative vaccines, encompassing over ten potential blockbuster varieties. These encompass areas such as cervical cancer, shingles, RSV infection, and other prevalent high-burden diseases, and have emerged as leading products in terms of development and clinical progress in
Having been honed and refined over the course of a decade, Recbio is poised to reap the benefits as several products are nearing commercialization.
Forward-looking statements
This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target", "believe", "potential" and "reasonably possible" or the negatives thereof or other variations thereon or comparable terminology (collectively, "forward-looking statements"), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management's beliefs, expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.
Please refer to the announcements published by the Company on the websites of The
Investor Inquiry:
Email: ir@recbio.cn
Tel: +86-0523-86818860
Media Inquiry:
Email: media@recbio.cn
Tel: +86-0523-86818860
Related Links:
https://www.recbio.cn/
View original content to download multimedia:https://www.prnewswire.com/news-releases/recbio-and-rongsheng-biotech-signed-a-strategic-cooperation-agreement-on-the-new-adjuvant-vaccine-project-302100410.html
SOURCE